CHRISTOPHER KAISER: Open Payments
NPI 1497314785 · WILMINGTON, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,421 in 159 payments from 25 companies in 2025. Trend: 2023 $1,795 · 2024 $2,786 · 2025 $3,421
Food & beverage: $3,344Education: $77
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 25 | $762 |
| GlaxoSmithKline, LLC. | 29 | $392 |
| GENZYME CORPORATION | 15 | $317 |
| Regeneron Healthcare Solutions, Inc. | 15 | $307 |
| Insmed, Inc. | 13 | $221 |
| United Therapeutics Corporation | 7 | $172 |
| Merck Sharp & Dohme LLC | 6 | $154 |
| Verona Pharma, Inc. | 8 | $144 |
| ANI Pharmaceuticals, Inc. | 6 | $119 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $115 |
Products named: DUPIXENT, NUCALA, AIRSUPRA, TEZSPIRE, BREZTRI, Tyvaso, Arikayce, ZERBAXA.
Industry payments across NC — which companies pay providers there.
